StartJAZZ • NASDAQ
add
Jazz Pharmaceuticals PLC
124,39 $
Efter lukketid:(0,00 %)0,00
124,39 $
Lukket: 27. jan., 16.04.46 GMT-5 · USD · NASDAQ · Ansvarsfraskrivelse
Seneste lukkekurs
122,04 $
Dagsinterval
122,12 $ - 124,83 $
Årsinterval
99,06 $ - 134,17 $
Markedsværdi
7,52 mia. USD
Gns. volumen
570,65 t
P/E-værdi
17,52
Udbytteprocent
-
Primær børs
NASDAQ
I nyhederne
Økonomi
Resultatopgørelse
Indtægt
Nettoindtægt
| (USD) | sep. 2024info | År til år-ændring |
|---|---|---|
Indtægt | 1,05 mia. | 8,52 % |
Driftsudgifter | 683,15 mio. | -2,07 % |
Nettoindtægt | 215,06 mio. | 46,48 % |
Overskudsgrad | 20,38 | 34,97 % |
Earnings per share | 6,61 | 36,57 % |
EBITDA | 425,44 mio. | 27,02 % |
Effektiv afgiftssats | -7,25 % | — |
Årsbalance
Samlede aktiver
Samlede passiver
| (USD) | sep. 2024info | År til år-ændring |
|---|---|---|
Kontanter og korttidsinvesteringer | 2,62 mia. | 64,40 % |
Samlede aktiver | 12,26 mia. | 9,39 % |
Samlede passiver | 8,08 mia. | 4,80 % |
Samlet egenkapital | 4,17 mia. | — |
Shares outstanding | 60,45 mio. | — |
Kurs/indre værdi | 1,77 | — |
Afkast af aktiver | 5,51 % | — |
Afkast af kapital | 6,53 % | — |
Pengestrøm
Nettoændring i likviditet
| (USD) | sep. 2024info | År til år-ændring |
|---|---|---|
Nettoindtægt | 215,06 mio. | 46,48 % |
Pengestrøm fra drift | 398,75 mio. | 29,80 % |
Pengestrøm fra investering | 214,09 mio. | 222,83 % |
Pengestrøm fra finansiering | 246,43 mio. | 413,95 % |
Nettoændring i likviditet | 862,33 mio. | 1.515,28 % |
Fri pengestrøm | 299,28 mio. | -4,88 % |
Om
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.
In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use.
The company is also a member of the Pharmaceutical Research and Manufacturers of America. Wikipedia
Administrerende direktør
Grundlagt
2003
Website
Ansatte
2.800
